Shilanski & Associates, Inc. Novo Nordisk A S Transaction History
Shilanski & Associates, Inc.
- $296 Million
- Q2 2024
A detailed history of Shilanski & Associates, Inc. transactions in Novo Nordisk A S stock. As of the latest transaction made, Shilanski & Associates, Inc. holds 5,138 shares of NVO stock, worth $581,878. This represents 0.25% of its overall portfolio holdings.
Number of Shares
5,138
Previous 5,417
5.15%
Holding current value
$581,878
Previous $695,000
5.47%
% of portfolio
0.25%
Previous 0.24%
Shares
10 transactions
Others Institutions Holding NVO
# of Institutions
1,963Shares Held
320MCall Options Held
5.16MPut Options Held
4.96M-
Jennison Associates LLC21.2MShares$2.4 Billion1.95% of portfolio
-
Morgan Stanley New York, NY14.6MShares$1.65 Billion0.16% of portfolio
-
Bank Of America Corp Charlotte, NC14.2MShares$1.61 Billion0.18% of portfolio
-
Ken Fisher Fisher Asset Management, LLC | Camas, Wa13.4MShares$1.51 Billion0.83% of portfolio
-
Fayez Sarofim & CO Houston, TX12.6MShares$1.42 Billion4.91% of portfolio
About NOVO NORDISK A S
- Ticker NVO
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 2,257,289,984
- Market Cap $256B
- Description
- Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...